Sponsored

Meet Ms Janine Rolfe, Cynata’s (ASX:CYP) new Non-Executive Director

September 06, 2022 09:35 AM AEST | By Aditi Sarkar
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

Highlights

  • Ms Janine Rolfe has joined Cynata as an independent Non-Executive Director
  • Ms Rolfe has more than 20 years of expertise in executive roles within different industry sectors, and she has worked both in-house and in private legal practice

Cynata Therapeutics Limited (ASX:CYP), a cell therapeutics company, onboards Ms Janine Rolfe as a new independent Non-Executive Director. The new appointment will be effective from 1 September 2022.

Ms Rolfe has over 20 years of experience in different industry sectors, where her various roles have included management, legal and governance. She has worked with complex global businesses and highly regulated industries. Before joining Cynata, Ms Rolfe worked with Link Administration Holdings Limited (Link Group), as General Counsel & Company Secretary. Prior to that position, she established Company Matters Pty Limited. She has worked both in-house (Qantas Airways Limited) and in private practice (Mallesons Stephen Jaques, now King & Wood Mallesons). Ms Rolfe is a member of the Australian Institute of Company Directors (AICD) and received a Bachelor of Economics and Bachelor of Laws (Honours) from the University of Sydney.

Image: © 2022 Kalkine Media®

Embed video

Cynata Therapeutics elaborates on its strong pipeline of clinical opportunities

About Cynata

Cynata specialises in stem cell and regenerative medicine, developing therapies based on its proprietary platform technology, Cymerus™.

Image: © 2022 Kalkine Media®

CYP-001 is the company’s lead product. It has proven positive safety and efficacy data for treating steroid-resistant acute graft-versus-host disease (aGvHD) in a Phase 1 trial. Presently, the company is planning a Phase 2 clinical trial in GvHD under a cleared IND from the US FDA.

Words from the new member

Image: © 2022 Kalkine Media®

Publication in a reputed journal

In a recent announcement, Cynata mentioned that the results of its research work describing the optimisation of Cymerus™ mesenchymal stem cells (MSCs) for the treatment of coronary artery disease (CAD) had been published in the Journal of Tissue Engineering and Regenerative Medicine. It is a highly reputed peer-reviewed journal, and Cynata undertook the study in collaboration with UNSW Sydney (the University of New South Wales). These exciting results suggest that Cymerus MSCs could play an important part in the management of CAD.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

Two ASX Listed Stocks Giving Bullish Indications

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.